Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Return on Equity (2022 - 2026)

Axsome Therapeutics' Return on Equity history spans 5 years, with the latest figure at 0.03% for Q1 2026.

  • On a quarterly basis, Return on Equity rose 2.0% to 0.03% in Q1 2026 year-over-year; TTM through Mar 2026 was 0.03%, a 2.0% increase, with the full-year FY2025 number at 0.03%, changed 0.0% from a year prior.
  • Return on Equity hit 0.03% in Q1 2026 for Axsome Therapeutics, down from 0.02% in the prior quarter.
  • Over the last five years, Return on Equity for AXSM hit a ceiling of 0.01% in Q3 2023 and a floor of 0.05% in Q1 2025.
  • Historically, Return on Equity has averaged 0.02% across 5 years, with a median of 0.02% in 2025.
  • Biggest five-year swings in Return on Equity: decreased -3bps in 2024 and later rose 2bps in 2025.
  • Tracing AXSM's Return on Equity over 5 years: stood at 0.01% in 2022, then grew by 26bps to 0.01% in 2023, then tumbled by -269bps to 0.04% in 2024, then surged by 41bps to 0.02% in 2025, then decreased by -17bps to 0.03% in 2026.
  • Business Quant data shows Return on Equity for AXSM at 0.03% in Q1 2026, 0.02% in Q4 2025, and 0.03% in Q3 2025.